B cell-based test in trials for MRSA detection

03/20/2012 | MedCityNews.com

A biosensor technology that uses genetically engineered white blood cells to rapidly diagnose methicillin-resistant staphylococcus aureus is undergoing clinical tests, according to diagnostics company Innovative Biosensors. The BioFlash-Dx technology is based on B cells that bind to pathogens. The company obtained $1.5 million of a targeted $2.7 million financing round to develop its platform for the detection of infections and cardiovascular disease.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Director of Operations - GBS
Mayo Clinic
Rochester, MN
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Senior Vice President, Clinical Affairs & Strategic Partnerships
America's Health Insurance Plans (AHIP)
Washington, DC